CytRx Completes Pre-IND Meeting With FDA on Planned Phase II Trial of Arimoclomol

CytRx has completed a meeting with representatives of the FDA prior to the submission of the company's investigational new drug (IND) application for its lead small molecule drug candidate arimoclomol for the treatment of amyotrophic lateral sclerosis.

The FDA's pre-IND meeting programs are designed to provide sponsors with advance guidance and input on drug development programs.